44
total announcements
APLLTD.NS · 15 min delayed
Key Stats · Yahoo Finance · as of 15 Oct 2026
Market Cap
₹15,577 Cr
P/E (TTM)
22.5
P/E (Forward)
16.2
EPS (TTM)
₹35.27
52W Low
₹635.80
52W High
₹998.00
Dividend Yield
1.50%
Beta
0.32
Price / Book
2.7
Debt / Equity
25.2
Revenue (TTM)
₹7,784 Cr
Gross Margin
70.56%
Operating Margin
10.89%
Alembic Pharmaceuticals Limited
Alembic Pharmaceuticals Limited has informed the Exchange about a copy of a newspaper publication regarding a tender inquiry for a 66KV Jagraon to Sidhwan BTL line for 66KV S/Stn Bazurg.
Alembic Pharmaceuticals Limited
Alembic Pharmaceuticals Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018 for the quarter and half year ended 30th September, 2026.
Alembic Pharmaceuticals Limited
Alembic Pharmaceuticals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015. The trading window will remain closed from 1st October, 2026 till 48 hours after the declaration of the Unaudited Financial Results of the Company, for the quarter and half year ending on 30th September, 2026.
Alembic Pharmaceuticals Limited
Alembic Pharmaceuticals Limited has informed the Exchange about a schedule of one-to-one meetings with institutional investors/analysts in Mumbai on September 23, 2026.
Alembic Pharmaceuticals Limited
Alembic Pharmaceuticals Limited has received the Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA) for the inspection conducted at its Bioequivalence Facility in Vadodara, Gujarat, from 3rd March to 7th March 2025. The inspection has been closed, and the company has taken this on record.
Alembic Pharmaceuticals Limited
Alembic Pharmaceuticals Limited has successfully completed an unannounced onsite Bioequivalence inspection by the USFDA at its Bioequivalence Facility in Vadodara, Gujarat, with no Form 483 observations.
Alembic Pharmaceuticals Limited
Alembic Pharmaceuticals Limited has informed the Exchange about the incorporation of a Wholly Owned Subsidiary (WOS) named Alembic Pharmaceuticals Global FZCO in Dubai, United Arab Emirates. The intimation was received on 7th September, 2026.
Alembic Pharmaceuticals Limited
Alembic Pharmaceuticals Limited has informed the Exchange about the schedule of one-to-one meetings with investors/analysts on September 1-2, 2026, in Mumbai and virtually.
Alembic Pharmaceuticals Limited
Alembic Pharmaceuticals Limited has informed the Exchange about the schedule of one-to-one meetings with investors/analysts on September 1-2, 2026, in Mumbai and virtually.
Alembic Pharmaceuticals Limited
Alembic Pharmaceuticals Limited has informed the Exchange about a newspaper advertisement related to notice of loss of equity share certificate(s) published in Indian Express and Financial Express on 25th August, 2026. The company is warning the public against purchasing or dealing with these equity shares certificates and is requesting claimants to send full details with documentary evidence to the company's RTA or the company within 15 days from the date of publication.
Alembic Pharmaceuticals Limited
Alembic Pharmaceuticals Limited has informed the Exchange about the appointment of Mr. Chirag Shukla as the new Company Secretary & Compliance Officer, effective August 20, 2026.
Alembic Pharmaceuticals Limited
Alembic Pharmaceuticals Limited has informed the Exchange about the opening of another special window for transfer and dematerialization of physical securities, as per SEBI Circular No. H0/38/13/11 (2)2026-MIRSD-POD/1/3750/2026 dated 31st January, 2026.
Alembic Pharmaceuticals Limited
Alembic Pharmaceuticals Limited has informed the Exchange about the resignation of a Director/KMP/SMP.
Alembic Pharmaceuticals Limited
Alembic Pharmaceuticals Limited has informed the Exchange regarding the resignation of Ms. Manisha Saraf as Company Secretary & Compliance Officer, effective August 10, 2026.
Alembic Pharmaceuticals Limited
Alembic Pharmaceuticals Limited has reported a strong Q1 FY27 with 26% year-on-year revenue growth, driven by growth across all major businesses, including a 7% growth in India branded business, 37% growth in International Generics, and 33% growth in API business. The company has also strengthened its execution leadership with the appointment of Mr. Ramesh Juneja as Sales and Marketing Head for Human Health business.
Alembic Pharmaceuticals Limited
Alembic Pharmaceuticals Limited has submitted the Exchange a copy of the Scrutinizers' report of the 16th Annual General Meeting held on August 05, 2026. The company has informed the Exchange regarding voting results.
Alembic Pharmaceuticals Limited
Alembic Pharmaceuticals Limited has held its 16th Annual General Meeting through video conferencing, where the company's audited financial statements for the year ended March 31, 2026, were adopted, and a dividend on equity shares for the financial year 2025-26 was declared. The company also appointed a new independent director and ratified the remuneration to the cost auditors for the financial year 2026-27.
Alembic Pharmaceuticals Limited
Alembic Pharmaceuticals Limited has published unaudited financial results for the quarter ended 30th June, 2026, showing a total income from operations of ₹2,149.77 crores and a net profit of ₹221.86 crores.
Alembic Pharmaceuticals Limited
Alembic Pharmaceuticals Limited has informed the Exchange about the link of recording of the post-results conference call held on 4th August, 2026. The audio recording is hosted on the company's website at https://alembicpharmaceuticals.com/quarterly-results.
Alembic Pharmaceuticals Limited
Alembic Pharmaceuticals Limited reported its consolidated financial results for the first quarter ended 30th June 2026, with revenue from operations increasing by 26% YoY to Rs.2150 Cr, and profit after tax at Rs. 173 Cr, up 12% YoY.